PDCD1 and carcinoma: Toripalimab as a novel PD-1 inhibitor has presented its promising efficacy in patients who developed chemo-refractory carcinomas (12, 18), whereas no study has ever investigated the effectiveness of toripalimab in chemo-resistant choriocarcinoma.